Abstract: This rotating electric machine has a rotor, stator core, field windings for multiple poles, and armature windings for the multiple poles. The rotor is rotatably supported about a shaft. Convex-shaped multiple salient pole sections are formed on the outer circumference of the rotor while arranged in the circumferential direction. The stator core is provided along the outer circumference of the rotor with an air gap from the rotor. Convex-shaped multiple teeth are formed on the inner circumference of the stator core while arranged in the circumferential direction. The field windings for the multiple poles are wound around each of the multiple teeth while insulated from the field windings.

Abstract: This rotating electrical machine has a rotor, stator core, field windings for multiple poles, and armature windings for the multiple poles. The rotor is rotatably supported about a shaft. Convex-shaped multiple salient pole sections are formed on the outer circumference of the rotor while arranged in the circumferential direction. The stator core is provided along the outer circumference of the rotor with an air gap from the rotor. Convex-shaped multiple teeth are formed on the inner circumference of the stator core while arranged in the circumferential direction. The field windings for the multiple poles are wound around each of the multiple teeth while insulated from the field windings.

Abstract: A field control device for a synchronous rotating machine includes: a target operating condition input unit; a first subtraction unit; a final-control-quantity control computation unit that accepts the final-control-quantity deviation and outputs a field-current correction demand value; an anticipatory computation unit that outputs a field-current anticipatory demand value based on the operating condition demand values input; an addition unit that adds the field-current correction demand value and the field-current anticipatory demand value; a second subtraction unit; and a field-current regulation device that adjusts the field current based on the field current deviation.

Abstract: A field control device for a synchronous rotating machine includes: a target operating condition input unit; a first subtraction unit; a final-control-quantity control computation unit that accepts the final-control-quantity deviation and outputs a field-current correction demand value; an anticipatory computation unit that outputs a field-current anticipatory demand value based on the operating condition demand values input; an addition unit that adds the field-current correction demand value and the field-current anticipatory demand value; a second subtraction unit; and a field-current regulation device that adjusts the field current based on the field current deviation.

Abstract: This rotating electric machine has a rotor, stator core, field windings for multiple poles, and armature windings for the multiple poles. The rotor is rotatably supported about a shaft. Convex-shaped multiple salient pole sections are formed on the outer circumference of the rotor while arranged in the circumferential direction. The stator core is provided along the outer circumference of the rotor with an air gap from the rotor. Convex-shaped multiple teeth are formed on the inner circumference of the stator core while arranged in the circumferential direction. The field windings for the multiple poles are wound around each of the multiple teeth while insulated from the field windings.

Abstract: This rotating electrical machine has a rotor, stator core, field windings for multiple poles, and armature windings for the multiple poles. The rotor is rotatably supported about a shaft. Convex-shaped multiple salient pole sections are formed on the outer circumference of the rotor while arranged in the circumferential direction. The stator core is provided along the outer circumference of the rotor with an air gap from the rotor. Convex-shaped multiple teeth are formed on the inner circumference of the stator core while arranged in the circumferential direction. The field windings for the multiple poles are wound around each of the multiple teeth while insulated from the field windings.

Abstract: The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.

Abstract: A dynamo electric machine includes a rotor having magnetic poles with permanent magnets and a stator having armature windings concentratedly wound around teeth. When the number of pole pairs of the magnetic poles of the rotor is P, diameter of the rotor is D (meters), and a spatial harmonic order of a predetermined harmonic component of an armature magnetomotive force of the rotor is N ((N=P to the 1.5th power)×(N to the minus 4-th power)×(the square of P)×D<0.6 (in meters).

Abstract: This invention provides a compound of the formula (I): 1

Abstract: The present invention has been made for the purpose of obtaining a permanent magnet type dynamo electric machine, and a permanent magnet type synchronous generator for wind power generation, each of which is capable of reducing an eddy current loss of a rotor while having a construction of an integral one-piece rotor yoke.

Abstract: This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

Abstract: The present invention relates to compounds of the formula wherein each A is independently halo; Y is —(CH2)m—, —C(O)— or —S(O)—; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 is phenyl substituted at the 2-position with a substituent selected from substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 is hydrogen or C1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.

Abstract: This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

Abstract: This invention provides a compound of the formula (I): 1

Abstract: The present invention relates to compounds of the formula 1

Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y1 is —(CH2)m—, C(O) or S(O); Y2 is N or CH; R1 and R2 are independently C1-4 alkyl; R3 is selected from the following: (a) optionally substituted —(CH2)p—C3-7 cycloalkyl; (b) optionally substituted —C5-7 alkyl; and (c) substituted —C1-4 alkyl; and (d) optionally substituted C7-9 bicycloalkyl; R4 is optionally substituted thiazolyl, imidazolyl or oxazolyl; X is S, —NH, —N—C1-4 alkyl or O; R5 is hydrogen or C1-4 alkyl; R6 is C1-4 alkyl or halo; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or S; and p is 0, 1, 2, 3, 4, 5 or 6. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Abstract: This invention provides a compound of the formula (I): 1

Abstract: This invention provides a compound of the formula (I): 1